Αρχική World News Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA... World News Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR Από Ogkologos - 28 Ιουλίου, 2025 855 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC 18 Σεπτεμβρίου, 2024 Thinking outside the chromosome – how ecDNA is challenging conventional thinking 11 Νοεμβρίου, 2022 Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance... 6 Οκτωβρίου, 2026 World Cancer Research Day: Celebrating Progress in Treating and Caring for... 13 Σεπτεμβρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS 6-Year-Old Uses Money From Lemonade Stand To Take Mom Out On... Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal... Mom’s Early-Stage Breast Cancer Discovered When She Undergoes Testing to Donate... Annual Multicancer Early Detection Test Not Associated with a Lower Incidence...